Drug Topics - February 2009 - (Page 60) VIEWPOINT The value of a Pharmacist Risk Manager Ken Baker, BS, PharmD, JD Recently, in a lecture before a group of pharmacy students, I asked them to imagine they had successfully graduated and were arriving at their first job. The new boss gives them their first assignment — to design a workflow plan significantly reducing the number of medication errors. The boss tells them the goal of their new plan for the pharmacy should be zero errors. The students and I then discussed how they could design such a plan and how valuable the students would be if they succeeded. I asked them how much more money they would be worth if they could set up a program that could stop just one $50,000 claim from occurring. A trained, experienced pharmacist risk manager has real value. It is now possible for a pharmacist to receive that kind of risk-management training. Currently, a handful of pharmacy schools offer advanced training in risk management. Within its Master of Science in Pharmacy program, the University of Florida is offering a part-time online major in patient safety and risk management. This master’s level degree program is particularly designed to provide students with the knowledge, skills, and ability to develop comprehensive clinical risk-management and patient-safety programs. According to David Brushwood, program director for the University of Florida’s Masters of Science in Pharmacy curriculum, the university was responding to student demand for a major in patient safety. “This major provides students with the opportunity to enter the growing field of healthcare risk management,” he said. Many states require pharmacies to implement continuous quality improvement programs as part of their prescription workflow. Even more states are considering such legislation. Within a few years, every community and hospital pharmacy in the United States will be developing, implementing, modifying, or using risk-management systems designed to reduce medication errors and improve patient safety. The demand for trained experts in the field of risk management will grow to meet the need. Their value will correspondingly increase. As state boards of pharmacy realize that merely having a quality-assurance plan is not enough, the value of a trained risk manager will become more apparent. Regulators, pharmacy and hospital executives, insurance companies, and patients will demand that every pharmacy have a system that not only Ken Baker is a pharmacist and an attorney with the Arizona law firm of Renaud Cook Drury Mesaros, PA. Contact him at ken@ kenbakerconsulting.com. W W W.D R U GTO P I C S .C O M 60 DRUG TOPICS Februar y 2009 COURTESY UNIVERSITY OF FLORIDA can reduce the number of medication errors, but actually reduces claims and embarrassing situations. Quality judged by outcomes will become the norm. This will force the profession to recognize the need for specialists trained to design, implement, and continuously improve healthcare delivery. In the last several years, profit margins have decreased while demands for services have increased. Prescription volume has multiplied; pharmacists and pharmacy technicians have been filling more prescriptions while the number of available staff has remained constant. It is not surprising medication errors and pharmacy malpractice claims have increased, along with demands for quality solutions. The University of Florida’s timing is excellent, and it is not alone in its efforts to train specialists in risk management and patient safety. Temple University School of Pharmacy has a certificate program for pharmacists and a masters program that trains experts, primarily for the pharmaceutical industry. St. Johns University and Purdue University also have programs that emphasize quality assurance in the pharmacy industry. I have to admit some prejudice, as I teach online courses in the University of Florida Masters in Science programs, including in its patient-safety and risk-management major. All these universities, however, are top pharmacy schools and pharmacists would do well to look at all of them. Anyone interested in more information should visit the schools’ websites. For the University of Florida Masters program, information can be found at http://pharmreg.dce.ufl.edu/, or pharmacists can contact the program director, Professor David Brushwood, at brushwood@cop.ufl.edu. They may also contact me at ken@ kenbakerconsulting.com. I will try to be objective. http://pharmreg.dceufl.edu http://WWW.DRUGTOPICS.COM
Table of Contents Feed for the Digital Edition of Drug Topics - February 2009 Drug Topics - February 2009 Contents Health-System Edition Group Attempts to Resurrect Pain Care Act HSE Business Management HSE Clinical Letters Up Front Up Front in Depth Community Practice Niche Pharmacies Serve Special Populations Special Report Oral Oncology Drugs New Drugs Update 2008 Approvals OTC New Products Viewpoint Drug Topics - February 2009 Drug Topics - February 2009 - Drug Topics - February 2009 (Page Cover1) Drug Topics - February 2009 - Drug Topics - February 2009 (Page Cover2) Drug Topics - February 2009 - Drug Topics - February 2009 (Page 1) Drug Topics - February 2009 - Drug Topics - February 2009 (Page 2) Drug Topics - February 2009 - Contents (Page 3) Drug Topics - February 2009 - Contents (Page 4) Drug Topics - February 2009 - Contents (Page 5) Drug Topics - February 2009 - Contents (Page 6) Drug Topics - February 2009 - Contents (Page 7) Drug Topics - February 2009 - Contents (Page 8) Drug Topics - February 2009 - Group Attempts to Resurrect Pain Care Act (Page H1) Drug Topics - February 2009 - HSE Business Management (Page H2) Drug Topics - February 2009 - HSE Business Management (Page H3) Drug Topics - February 2009 - HSE Business Management (Page H4) Drug Topics - February 2009 - HSE Business Management (Page H5) Drug Topics - February 2009 - HSE Clinical (Page H6) Drug Topics - February 2009 - HSE Clinical (Page H7) Drug Topics - February 2009 - HSE Clinical (Page H8) Drug Topics - February 2009 - HSE Clinical (Page 9) Drug Topics - February 2009 - HSE Clinical (Page 10) Drug Topics - February 2009 - Letters (Page 11) Drug Topics - February 2009 - Up Front (Page 12) Drug Topics - February 2009 - Up Front (Page 13) Drug Topics - February 2009 - Up Front in Depth (Page 14) Drug Topics - February 2009 - Up Front in Depth (Page 15) Drug Topics - February 2009 - Up Front in Depth (Page 16) Drug Topics - February 2009 - Up Front in Depth (Page 17) Drug Topics - February 2009 - Up Front in Depth (Page 18) Drug Topics - February 2009 - Up Front in Depth (Page 19) Drug Topics - February 2009 - Up Front in Depth (Page 20) Drug Topics - February 2009 - Community Practice (Page 21) Drug Topics - February 2009 - Niche Pharmacies Serve Special Populations (Page 22) Drug Topics - February 2009 - Niche Pharmacies Serve Special Populations (Page 23) Drug Topics - February 2009 - Niche Pharmacies Serve Special Populations (Page 24) Drug Topics - February 2009 - Niche Pharmacies Serve Special Populations (Page 25) Drug Topics - February 2009 - Niche Pharmacies Serve Special Populations (Page 26) Drug Topics - February 2009 - Niche Pharmacies Serve Special Populations (Page 27) Drug Topics - February 2009 - Special Report Oral Oncology Drugs (Page 28) Drug Topics - February 2009 - Special Report Oral Oncology Drugs (Page 29) Drug Topics - February 2009 - Special Report Oral Oncology Drugs (Page 30) Drug Topics - February 2009 - Special Report Oral Oncology Drugs (Page 31) Drug Topics - February 2009 - Special Report Oral Oncology Drugs (Page 32) Drug Topics - February 2009 - Special Report Oral Oncology Drugs (Page 33) Drug Topics - February 2009 - Special Report Oral Oncology Drugs (Page 34) Drug Topics - February 2009 - Special Report Oral Oncology Drugs (Page 35) Drug Topics - February 2009 - Special Report Oral Oncology Drugs (Page 36) Drug Topics - February 2009 - Special Report Oral Oncology Drugs (Page 37) Drug Topics - February 2009 - Special Report Oral Oncology Drugs (Page 38) Drug Topics - February 2009 - Special Report Oral Oncology Drugs (Page 39) Drug Topics - February 2009 - New Drugs Update 2008 Approvals (Page 40) Drug Topics - February 2009 - New Drugs Update 2008 Approvals (Page 41) Drug Topics - February 2009 - New Drugs Update 2008 Approvals (Page 42) Drug Topics - February 2009 - New Drugs Update 2008 Approvals (Page 43) Drug Topics - February 2009 - New Drugs Update 2008 Approvals (Page 44) Drug Topics - February 2009 - New Drugs Update 2008 Approvals (Page 45) Drug Topics - February 2009 - New Drugs Update 2008 Approvals (Page 46) Drug Topics - February 2009 - New Drugs Update 2008 Approvals (Page 47) Drug Topics - February 2009 - New Drugs Update 2008 Approvals (Page 48) Drug Topics - February 2009 - New Drugs Update 2008 Approvals (Page 49) Drug Topics - February 2009 - OTC (Page 50) Drug Topics - February 2009 - OTC (Page 51) Drug Topics - February 2009 - OTC (Page 52) Drug Topics - February 2009 - New Products (Page 53) Drug Topics - February 2009 - New Products (Page 54) Drug Topics - February 2009 - New Products (Page 55) Drug Topics - February 2009 - New Products (Page 56) Drug Topics - February 2009 - New Products (Page 57) Drug Topics - February 2009 - New Products (Page 58) Drug Topics - February 2009 - New Products (Page 59) Drug Topics - February 2009 - Viewpoint (Page 60) Drug Topics - February 2009 - Viewpoint (Page Cover3) Drug Topics - February 2009 - Viewpoint (Page Cover4)
For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.